Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sovalutinib, Solutumab, and Tegeo in Advanced Pancreatic Cancer
NCT05958849Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Aug 2023
- Primary completion
- Jul 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of surufatinib in pancreatic cancer (PC), sponsored by Zhejiang Cancer Hospital. Status: unknown.
02
Drugs
surufatinib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05958849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05958849.